Introduction: A single dose or short course of primaquine given to
people infected with malaria may reduce transmission of Plasmodium
falciparum through its effects on gametocytes. Primaquine is also known
to cause haemolysis in people with variants of glucose-6-phosphate
dehydrogenase (G6PD) deficiency. The objective of this systematic review
was to assess the risk of adverse effects in people with G6PD deficiency
given primaquine or other 8-aminoquinoline (8AQ) as a single dose or
short course (less than 7 days).
Methods and analysis: We will search the following databases: Cochrane
Infectious Diseases Group Specialized Register, the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS.
Prospective cohort studies, randomised and quasi-randomised trials that
evaluated 8AQs for whatever reason in adults or children with a known
G6PD deficiency will be included. Two authors will independently assess
each study for eligibility, risk of bias and extract data.
Ethics and dissemination: This systematic review will be published in a
peer-reviewed journal. Brief reports of the review findings will be
disseminated directly to the appropriate audiences and the WHO Technical
Expert Group in Malaria Chemotherapy. As no primary data collection will
be undertaken, no additional formal ethical assessment and informed
consent are required.
Protocol registration in PROSPERO: The protocol is registered with
PROSPERO, registration number CRD42013006518.
Uthman, O.A.; Saunders, R.; Sinclair, D.; Graves, P.; Gelband, H.; Clarke, A.; Garner, P. Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies. BMJ Open (2014) 4 (5) e004664. [DOI: 10.1136/bmjopen-2013-004664]
Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies